Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:15489334, PubMed:9714779). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334)
Expressed in aortic smooth muscle cells, heart, placenta, skeletal muscle and pancreas and, to a much lesser extent, in brain, liver and lung
Composed of a C-terminal catalytic domain containing two putative divalent metal sites and an N-terminal regulatory domain which contains two homologous allosteric cGMP-binding regions, A and B
No mutation information available.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to PDE5A, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 36
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT01803828 | Diabetic Cardiomyopathy, Diabetes Mellitus Type 2 | REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs | PHASE4 | COMPLETED |
| NCT02611258 | Cushing's Syndrome Cardiomyopathy | Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs | PHASE2 | COMPLETED |
| NCT02611336 | Acromegaly Cardiomyopathy | Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy | PHASE2 | COMPLETED |
| NCT01359670 | Duchenne Muscular Dystrophy | Tadalafil and Sildenafil for Duchenne Muscular Dystrophy | EARLY_PHASE1 | COMPLETED |
| NCT01197469 | Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension | Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension? | PHASE2 | COMPLETED |
| NCT01070511 | Becker Muscular Dystrophy | Tadalafil in Becker Muscular Dystrophy | PHASE4 | COMPLETED |